Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 24, 2026

Marketeam.ai Unveils RL-KPI at NVIDIA GTC: Breakthrough AI Training Method Extends Deterministic Reward Learning to Non-Deterministic Business Outcomes

View original at finance.yahoo.com
Marketeam.ai Unveils RL-KPI at NVIDIA GTC: Breakthrough AI Training Method Extends Deterministic Reward Learning to Non-Deterministic Business Outcomes Revolutionary Technology Enables AI Models to Optimize for Real Business KPIs, Including Delayed, Multi-Objective Marketing Results; Customers See 6X ROI, and Significa…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RL-KPI represents one of the first successful extensions of deterministic reward learning principles to non-deterministic business outcomes

    60% confidence
  • Customers see 6X ROI and significant CAC reduction within 6 to 8 weeks

    60% confidence
  • Marketeam has cracked the code on training AI models to optimize for the messy, delayed, multi-objective reality of business performance

    60% confidence
  • The announcement marks a fundamental shift from training AI models on single human user preferences to training them on actual business outcomes measured through real-world campaign telemetry, conversion data, and KPI performance aggregated over time

    60% confidence
  • Conversion data can take 14-90 days to mature according to Google's attribution models

    60% confidence
  • This is one of the first successful applications of verifiable reward learning principles to non-deterministic business metrics at production scale

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com